Paul Ford

2.2k total citations
33 papers, 1.1k citations indexed

About

Paul Ford is a scholar working on Pulmonary and Respiratory Medicine, Immunology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Paul Ford has authored 33 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 7 papers in Immunology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Paul Ford's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (12 papers), Sports Performance and Training (5 papers) and Galectins and Cancer Biology (5 papers). Paul Ford is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (12 papers), Sports Performance and Training (5 papers) and Galectins and Cancer Biology (5 papers). Paul Ford collaborates with scholars based in United Kingdom, United States and Belgium. Paul Ford's co-authors include Jon L. Oliver, Marjan Moosavi, Mark De Ste Croix, Craig A. Williams, Rhodri S. Lloyd, Kevin Till, Ian M. Adcock, Kazuhiro Ito, Peter J. Barnes and Ann Fieuw and has published in prestigious journals such as Cancer Research, The FASEB Journal and Biochemical Society Transactions.

In The Last Decade

Paul Ford

31 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Ford United Kingdom 14 286 264 262 229 145 33 1.1k
Koya Suzuki Japan 18 178 0.6× 139 0.5× 75 0.3× 116 0.5× 94 0.6× 94 876
Brian J. Sharkey United States 18 30 0.1× 63 0.2× 245 0.9× 37 0.2× 143 1.0× 63 974
Jenny Thomas Australia 12 41 0.1× 39 0.1× 98 0.4× 53 0.2× 240 1.7× 21 1.1k
Mary Malakellis Australia 18 358 1.3× 16 0.1× 214 0.8× 82 0.4× 37 0.3× 32 1.3k
Jeffrey Thomas United States 15 39 0.1× 90 0.3× 79 0.3× 90 0.4× 13 0.1× 52 775
Robert J. Coughlan Ireland 18 182 0.6× 213 0.8× 82 0.3× 7 0.0× 187 1.3× 53 1.2k
Emma Hamilton Australia 19 192 0.7× 230 0.9× 268 1.0× 16 0.1× 17 0.1× 58 1.3k
Patricia E. Durning United States 15 109 0.4× 29 0.1× 36 0.1× 38 0.2× 34 0.2× 25 968
Christopher Klenk Switzerland 16 56 0.2× 65 0.2× 50 0.2× 24 0.1× 26 0.2× 36 717
Stuart Silverman United States 13 185 0.6× 45 0.2× 781 3.0× 10 0.0× 38 0.3× 35 1.3k

Countries citing papers authored by Paul Ford

Since Specialization
Citations

This map shows the geographic impact of Paul Ford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Ford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Ford more than expected).

Fields of papers citing papers by Paul Ford

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Ford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Ford. The network helps show where Paul Ford may publish in the future.

Co-authorship network of co-authors of Paul Ford

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Ford. A scholar is included among the top collaborators of Paul Ford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Ford. Paul Ford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ford, Paul, Michael Kreuter, Kevin K. Brown, et al.. (2024). An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis. ERJ Open Research. 10(1). 636–2023. 2 indexed citations
2.
3.
Khanna, Dinesh, Christopher P. Denton, Daniel E. Furst, et al.. (2023). A 24‐Week, Phase IIa, Randomized, Double‐Blind, Placebo‐Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology. 75(8). 1434–1444. 15 indexed citations
4.
Salgado-Polo, Fernando, Minos–Timotheos Matsoukas, Florence Marsais, et al.. (2023). Autotaxin facilitates selective LPA receptor signaling. Cell chemical biology. 30(1). 69–84.e14. 20 indexed citations
5.
6.
Cottin, Vincent, Christian A. Seemayer, Paul Ford, et al.. (2021). Results of a phase 2 study of GLPG1205 for idiopathic pulmonary fibrosis (PINTA). RCT2904–RCT2904. 2 indexed citations
7.
McLellan, T. M., Peter M. George, Paul Ford, et al.. (2020). Idiopathic pulmonary fibrosis: airway volume measurement identifies progressive disease on computed tomography scans. ERJ Open Research. 6(1). 290–2019. 8 indexed citations
8.
Lancaster, Lisa, et al.. (2020). Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis. Contemporary Clinical Trials. 100. 106227–106227. 9 indexed citations
9.
Sinclair, Kenneth, Stephanie T. Yerkovich, Peter Hopkins, et al.. (2020). The autotaxin-lysophosphatidic acid pathway mediates mesenchymal cell recruitment and fibrotic contraction in lung transplant fibrosis. The Journal of Heart and Lung Transplantation. 40(1). 12–23. 8 indexed citations
10.
Vuong, Lynda, Claire Rooney, Brian J. McHugh, et al.. (2019). An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade. Cancer Research. 79(7). 1480–1492. 104 indexed citations
11.
12.
Santermans, Eva, Paul Ford, Michael Kreuter, et al.. (2019). Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design. Advances in Therapy. 36(11). 3059–3070. 5 indexed citations
13.
Maher, Toby M., Michael Kreuter, David J. Lederer, et al.. (2019). Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). BMJ Open Respiratory Research. 6(1). e000422–e000422. 78 indexed citations
14.
Doescher, Mark P., et al.. (2012). Satisfaction of Family Physicians Working in Community Health Centers. The Journal of the American Board of Family Medicine. 25(4). 470–476. 7 indexed citations
15.
Ford, Paul, Mark De Ste Croix, Rhodri S. Lloyd, et al.. (2011). The Long-Term Athlete Development model: Physiological evidence and application. Journal of Sports Sciences. 29(4). 389–402. 304 indexed citations
16.
Adcock, Ian M., Pai-Chien Chou, Andrew Durham, & Paul Ford. (2009). Overcoming steroid unresponsiveness in airways disease. Biochemical Society Transactions. 37(4). 824–829. 13 indexed citations
17.
Ford, Paul, Richard Bailey, D. A. Coleman, Kate Woolf‐May, & Ian Swaine. (2007). Activity Levels, Dietary Energy Intake, and Body Composition in Children Who Walk to School. Pediatric Exercise Science. 19(4). 393–407. 27 indexed citations
18.
Adcock, Ian M., Paul Ford, Kazuhiro Ito, & Peter J. Barnes. (2006). Epigenetics and airways disease. Respiratory Research. 7(1). 21–21. 120 indexed citations
19.
Ford, Paul, et al.. (2006). Balancing in Ethical Deliberation: Superior to Specification and Casuistry. The Journal of Medicine and Philosophy A Forum for Bioethics and Philosophy of Medicine. 31(5). 483–497. 20 indexed citations
20.
Peterson, Verlyn M., James R. Murphy, Terri Haddix, et al.. (1988). Identification of Novel Prognostic Indicators in Burned Patients. The Journal of Trauma: Injury, Infection, and Critical Care. 28(5). 632–637. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Koya Suzuki Breakdown of academic impact, for papers by Brian J. Sharkey Breakdown of academic impact, for papers by Jenny Thomas Breakdown of academic impact, for papers by Mary Malakellis Breakdown of academic impact, for papers by Jeffrey Thomas Breakdown of academic impact, for papers by Robert J. Coughlan Breakdown of academic impact, for papers by Emma Hamilton Breakdown of academic impact, for papers by Patricia E. Durning Breakdown of academic impact, for papers by Christopher Klenk Breakdown of academic impact, for papers by Stuart Silverman
Rankless by CCL
2026